ID family may contribute to the commitment of haematopoietic precursors to an LC phenotype. An acquisition of Id2 and loss of PAX5 have been regarded as key factors in the transdifferentiation from a B-ALL to a LC/dentritic phenotype. 5 Little is known about the mechanisms by which Id2 regulates myeloid development. It is conceivable that transcription factors of the bHLH protein and Ets protein families may act downstream of ID2 and modulate myeloid development and proliferation. The divergent differentiation patterns reported here represent another example of the plasticity of haematopoietic cells that could, at least in part, be mediated by transcription factors including ID2 and its target genes.
Chronic lymphocytic leukemia (CLL) shows significant familial predisposition, yet few genes have been associated with disease risk. We have used high-resolution single nucleotide polymorphism (SNP) arrays to study familial CLL and lymphoproliferative disorders (LPDs), focusing on a cohort of 44 families that includes 58 individuals with CLL (Supplementary Table 1 ). Thirty-one of these families met the classic definition of familial CLL, namely at least two first degree relatives with CLL, whereas the remaining thirteen families had a proband with CLL and at least one first degree relative with another LPD. 1 A parallel experiment was undertaken in 103 sporadic CLL patients enrolled on our prospective CLL natural history study and whose data were available for comparison. All subjects on both studies signed written informed consent before participation. Gene expression profiling was also performed on the CLL tumor samples when RNA could be obtained.
The SNP array data from the CLL tumors were analyzed initially using the GISTIC method 2 (Supplementary Figure 1) and showed 13q deletion in 48% of these familial CLLs, trisomy 12 in 15.5%, 11q deletion in only 3.4% and 17p deletion in 6.9% (Supplementary  Table 2 and Supplementary Figure 1) . 11q deletion was seen in only 2 of 58 samples (Supplementary Figure 1, Supplementary Table 2 ), suggestive of a low frequency in familial CLL as we previously reported. 3 Otherwise, the pattern of somatic abnormalities was similar in familial and sporadic CLLs (Supplementary Table 2 ).
Detailed manual review of the 13q deletion region common in CLL revealed that family A in Supplementary Table 1 carries a germline deletion located telomeric to the commonly defined minimal region of deletion around miR-15a and miR-16 --1, and centered instead on the DLEU7 gene. The affected family includes a father with CLL (generation 1) and his four children, three of whom also developed CLL (generation 2, Figure 1a) . The three unaffected children of individual A-2A were assessed for evidence of monoclonal B cell lymphocytosis (MBL) 4 with four-color flow cytometry and PCR to detect monoclonal IgH rearrangement (Supplementary Figure 2) . These individuals had no evidence of MBL as yet but are young. The germline deletion at 13q in this family extends 525 kb on chromosome 13, from position 49 935 614 to 50 461 103, and includes the DLEU7 and RNASEH2B genes (Figures 1b and c) . A germline copy number variant (CNV) was not seen at this location in any other individual studied in this experiment (Figure 1b ), in our parallel sporadic experiment, or in 143 other normal DNAs from individuals with solid tumors. This deletion excludes the commonly recognized minimal region of deletion around DLEU2, miR-15a and miR-16 --1 (Figures 1b and c) , loss of which has been shown in knockout animals to result in a CLL-like disease. 5 However, recent work has suggested that DLEU7 can function as a tumor suppressor gene in CLL, 6 and that the minimal region of 13q deletion in CLL may also include DLEU7. Furthermore, a mouse model carrying conditional deletion of DLEU7, RNASEH2B and the miR-15a/miR-16-1 region in B cells develops CLL preferentially to MBL or NHL. 8 These data taken together support a role for this genomic region in the pathogenesis of CLL.
We found further support for DLEU7 acting as a tumor suppressor gene in CLL when we examined the affected children in generation 2, A-1A and A-2A, both of whom carry this deletion in their germline saliva samples and show deletion of the other allele in their tumor (Figure 1c ). In the tumors, A-1A had a Accepted article preview online 7 February 2012; advance online publication, 2 March 2012 significantly longer deletion at the other allele, resulting in monoallelic deletion of miR-15a/16-1 with biallelic deletion of DLEU7 and RNASEH2B (Figure 1c) . By contrast, A-2A showed loss of the second allele only at the site of the germline deletion (Figure 1c) . The CLL from this individual A-2A therefore has a 13q deletion that excludes the commonly recognized minimal region of deletion and includes only the DLEU7 region, consistent with DLEU7 as the primary tumor suppressor targeted by 13q deletion in this patient. These findings in both individuals suggest that loss of the second allele of DLEU7 may be a mechanism of CLL development, consistent with DLEU7 acting as a tumor suppressor gene in CLL, as previously reported. 6, 9 To confirm the presence of this germline CNV, we used a Taqman-based copy number assay with a probe for the DLEU7 gene (Figure 1d ). The normal germline of A-1A, A-2A and A-23U clearly shows just one copy of DLEU7, consistent with the results of the SNP array data. The tumor samples for A-1A and A-2A show significantly reduced copy number in this assay, near zero for A-1A and B0.5 copies for A-2A. This finding in A-2A is because of mosaicism within the tumor as the sample was 499% pure. Finally, using the gene expression data we looked at DLEU7 expression in the CLLs of the two affected individuals from this family compared with normal B cells, CLLs without 13q deletion and CLLs with mono-or biallelic 13q deletion. The CLLs from the individuals in Family A show very low DLEU7 expression comparable to the low expression of all other CLLs (Figure 1e) .
The GISTIC analysis also identified 6p25 amplification (Supplementary Figure 1B ) in both tumor and germline of two affected individuals with CLL in family B (Figure 2a) . Like family A, this family also shows apparently autosomal dominant Mendelian inheritance of CLL. Five of eleven siblings of generation 2 were affected with CLL or another LPD. One of those affected siblings had five children, of whom three were also affected with CLL, with disease onset in their 50s (generation 3). Generation 4 is mostly in their fourth decade of life and therefore younger than the expected age of onset of CLL (Supplementary Table 1) ; we again assessed the unaffected individuals in generations 3 and 4 for MBL and did not find it (Supplementary Figure 2) .
Visual inspection of the SNP array data confirmed a germline copy number gain at 6p25, spanning from the telomere to 720 kb (Figures 2b and c) . A known germline CNV is present in this region, labelled in Figure 2b , but the region of increased copy number in this family is significantly larger and encompasses the entire IRF4 gene (Figures 2b and c) . This gain was present in both affected individuals tested in generation 3 and transmitted by each to one of their two children in generation 4, confirming its germline presence (Figures 2a --c) . We again used quantitative PCR with TaqMan to confirm the 6p gain, and this experiment showed approximately four copies of IRF4 in the individuals with 6p25 gain (Figure 2d) . Assessment of this locus in an additional 43100 cancer specimens spanning 26 cancer types 10 did not reveal any other samples with a CNV this size. This germline gain was absent from the unaffected individuals in generation 3, their children in generation 4 and all of the other 159 individuals with CLL analyzed in our combined dataset, indicating that it is likely a private event.
This region of 6p gain contains four known protein coding genes: EXOC2, DUSP22, HUS1B and IRF4 (Figures 2b and c) . To identify mutations in these loci, we sequenced the coding regions of all four genes in this family and 84 other familial CLLs, and found no somatic mutations or novel germline variants. As the 3 0 UTR of IRF4 has been implicated in CLL risk by genome wide association study (GWAS), 11, 12 we also sequenced the 5 0 and 3
0
UTRs of IRF4 in this family and six other CLLs, yet found no somatic mutations or novel SNPs (data not shown).
We next compared expression of the four genes in this region between the 2 CLLs with 6p gain and the 144 other CLLs that we profiled, to determine if any of the four genes was altered in individuals with germline gain. We found a significant decrease in IRF4 expression in the CLLs with the gain (P-value o0.0001; Figure 2e ), whereas the other three genes were unchanged. Although the risk allele identified by GWAS at rs872071 has been previously associated with reduced IRF4 expression, 12 we see if anything a trend toward increased IRF4 expression with the GG risk allele (Figure 2e ). These findings have been further confirmed by quantitative PCR (P ¼ 0.006; Figure 2f ). Although the mechanisms by which the SNP risk allele and our 6p gain contribute to CLL pathogenesis remain to be elucidated, many lines of evidence implicate IRF4 in B-cell biology and suggest it as the target of the gain. IRF4 is somatically mutated in 1.5% of CLLs 13 and translocation breakpoints near IRF4 have been previously described in CLL.
14 Mice lacking IRF4 have a block at a late stage of B-cell maturation and develop generalized lymphadenopathy. 15 These data together with the GWAS findings and fine mapping 11, 12 suggest that germline gain of the IRF4 locus may predispose individuals in this family to CLL.
In conclusion, we report two germline CNVs associated with the development of CLL in two families with Mendelian-type inheritance of CLL. Both CNVs involve genes previously implicated in CLL pathogenesis and their discovery suggests that germline CNVs may be a novel mechanism of predisposition to CLL.
